Hormonal
Higher visceral adipose tissue (VAT) is independently associated with greater impairment in left ventricular peak circumferential strain (Ecc), indicating reduced myocardial contractility, regardless of cardiorespiratory fitness (CRF) or other regional fat depots.
Focus on reducing visceral fat (belly fat) rather than just total body weight. Even if you are not obese, high visceral fat is linked to early heart muscle dysfunction. Cardiovascular exercise and weight management are key to reducing this specific fat depot.
In adjusted analysis, higher amount of VAT was significantly associated with higher Ecc suggesting greater impairment in LV strain after adjustment for traditional CVD risk factors... The association remained significant after further adjustment for CRF... and other fat depots
Why this rating
Large population-based cohort (n=1089), rigorous adjustment for confounders, but cross-sectional design limits causal inference.
Source
Regional adiposity, cardiorespiratory fitness, and left ventricular strain: an analysis from the Dallas Heart Study
Nitin Kondamudi et al. · Journal of Cardiovascular Magnetic Resonance · 2021
DOI 10.1186/s12968-021-00757-w
More from this paper
- Higher cardiorespiratory fitness (CRF) is independently associated with more favorable left ventricular contractility (lower Ecc), independent of visceral fat levels and other risk factors.Good
- Lower-body fat (LBF) is associated with more favorable left ventricular contractility, potentially acting as a metabolic sink that protects against ectopic fat deposition.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →